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ABSTRACT
Aims The association between lung function and
cardiac markers and heart failure (HF) has been little
studied in the general older population. We have
examined the association between lung function and
airway obstruction with cardiac markers N-terminal pro-
brain natriuretic peptide (NT-proBNP) and cardiac
troponin T (cTnT) and risk of incident HF in older men.
Methods and results Prospective study of 3242 men
aged 60–79 years without prevalent HF or myocardial
infarction followed up for an average period of 13 years,
in whom 211 incident HF cases occurred. Incident HF
was examined in relation to % predicted FEV1 and FVC.
The Global Initiative on Obstructive Lung Diseases
spirometry criteria were used to deﬁne airway
obstruction. Reduced FEV1, but not FVC in the normal
range, was signiﬁcantly associated with increased risk of
HF after adjustment for established HF risk factors
including inﬂammation. The adjusted HRs comparing
men in the 6–24th percentile with the highest quartile
were 1.91 (1.24 to 2.94) and 1.30 (0.86 to 1.96) for
FEV1 and FVC, respectively. FEV1 and FVC were
inversely associated with NT-proBNP and cTnT, although
the association between FEV1 and incident HF remained
after adjustment for NT-proBNP and cTnT. Compared
with normal subjects (FEV1/FVC ≥0.70 and FVC≥80%),
moderate or severe (FEV1/FVC <0.70 and FEV1 <80%)
airﬂow obstruction was independently associated with
HF ((adjusted relative risk 1.59 (1.08 to 2.33)). Airﬂow
restriction (FEV1/FVC ≥0.70 and FVC <80%) was not
independently associated with HF.
Conclusions Reduced FEV1 reﬂecting airﬂow
obstruction is associated with cardiac dysfunction and
increased risk of incident HF in older men.
INTRODUCTION
COPD is common in the elderly and is associated
with increased cardiovascular (CVD) morbidity and
mortality.1 2 More recently, it has been established
that COPD is common in patients with heart
failure (HF) and that patients with COPD are at
increased risk of developing HF.3 4 The COPD–HF
association could reﬂect shared common risk
factors such as smoking, diabetes, obesity and
inﬂammation.2 3 5 COPD has also been linked to
cardiac stress and myocardial injury.6–9 The associ-
ation between lung function and incident HF, in
contrast to CVD,10 has been less studied at popula-
tion level, especially among older people. However,
a few prospective population studies have shown an
association between reduced lung function as mea-
sured by the FEV1, vital capacity (VC) or the
FEV1/FVC ratio and incident HF,11–16 although
this has not been observed in all studies.17 Reduced
and low normal lung function measured by FEV1
has been associated with increased risk of HF14–16
independent of inﬂammatory markers. The Global
Initiative for Chronic Obstructive Lung Diseases
(GOLD) classiﬁcation deﬁnes airﬂow obstruction
by FEV/FVC ratio <0.70.18 However, normal
ageing is associated with lung function declines that
often lead to an FEV1/FVC ratio <0.70 for indivi-
duals over 65 years, which may lead to misclassiﬁ-
cation of airway obstruction.19 Although one study
in the elderly has shown that a low FEV1/FVC
ratio (lowest 5th percentile) is associated with
increased HF risk,16 the risk associated with mild
airﬂow obstruction in the older population is less
clear and the relationship between airﬂow obstruc-
tion severity based on the spirometric GOLD classi-
ﬁcation of lung impairment18 and HF has not been
studied in the older general population.
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Key messages
What is the key question?
▸ What is the association between reduced lung
function and mild airﬂow obstruction with
cardiac dysfunction and risk of incident heart
failure (HF) in older people.
What is the bottom line?
▸ Reduced lung function reﬂecting moderate or
severe airﬂow obstruction is associated with
increased risk of HF, which is to some extent
associated with cardiac dysfunction.
Why read on?
▸ We have shown that the Global Initiative on
Obstructive Lung Diseases criteria for deﬁning
airﬂow obstruction based on spirometry can
lead to identiﬁcation of older adults at high
risk of HF.
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High-sensitivity cardiac troponin T (cTnT), a biomarker of
cardiomyocyte injury, and N-terminal pro-brain natriuretic
peptide (NT-proBNP), a marker of left ventricular wall stress,
have both been associated with increased HF risk.20–22
NT-proBNP and cTnT have been shown to be raised in patients
hospitalised with COPD.7 8 9 Whether such changes are seen in
those with mild airﬂow obstruction or low normal lung function
has been little studied in the general older population. We,
therefore, examined the associations between pulmonary func-
tion and risk of HF in older men without prevalent myocardial
infarction (MI) or HF and assessed to what extent the associ-
ation is related to inﬂammation and cardiac dysfunction
(NT-proBNP and cTnT). We have also examined the association
between restrictive and obstructive ventilatory patterns with
incident HF using a modiﬁcation of the spirometric GOLD clas-
siﬁcation for lung function impairment.17
SUBJECTS AND METHODS
The British Regional Heart Study is a prospective study invol-
ving 7735 men aged 40–59 years drawn from one general prac-
tice in each of 24 British towns, who were screened between
1978 and 1980.23 The population studied was socioeconomic-
ally representative and comprised predominantly white
Europeans (>99%). In 1998–2000, all surviving men, then
aged 60–79 years, were invited for a 20th-year follow-up exam-
ination, on which the current analyses are based. All men com-
pleted a mailed questionnaire providing information on their
lifestyle and medical history, had a physical examination and
provided a fasting blood sample. The samples were frozen and
stored at −20°C on the day of collection and transferred in
batches for storage at −70°C until analysis, carried out after no
more than one freeze–thaw cycle. The 12-lead ECGs were
recorded using a Siemens Sicard 460 instrument and were ana-
lysed using Minnesota Coding deﬁnitions at the University of
Glasgow ECG core laboratory. Men were asked whether a
doctor had ever told them that they had angina or MI, HF or
stroke; details of their medications were recorded at the examin-
ation including use of bronchodilators (British National
Formulary code 3.1). In total, 4252 men (77% of available sur-
vivors) attended for examination. A total of 3706 men had lung
function measures and blood measures of NT-proBNP and
cTnT. We excluded men with prior HF or MI (N=464) at
examination, leaving 3242 men for analysis.
CVD risk factor measurements at 1998–2000
Anthropometric measurements including body weight and
height were carried out. Details of measurement and classiﬁca-
tion methods for smoking status, physical activity, social class,
alcohol intake, blood pressure and blood lipids in this cohort
have been described.24 25 C-reactive protein (CRP) (marker of
inﬂammation) was assayed by ultra sensitive nephelometry
(Dade Behring, Milton Keynes, UK). NT-proBNP was deter-
mined using the Elecsys 2010 (Roche Diagnostics, Burgess Hill,
UK).22 Troponin T was measured by a high-sensitivity method
on an e411 (Roche Diagnostics, Burgess Hill, UK) using the
manufacturer’s calibrators and quality control material. The low
control CV was 6.6%, the high control CV 3.0% and the assay
limit of detection was 3 pg/mL. Electrocardiographic left ven-
tricular hypertrophy (LVH) was deﬁned according to relevant
Minnesota codes (codes 3.1 or 3.3). Atrial ﬁbrillation (AF) was
deﬁned according to Minnesota codes 8.3.1 and 8.3.3.
Lung function
FEV1 and FVC were measured using a Vitalograph compact II
spirometer with the subject seated. We used predictive equations
for FEV1 and FVC derived from the general population Health
Survey for England for males aged >25 years to obtain pre-
dicted lung function values taking account of age and height.26
The following equations were used:
predicted FEV1 ¼  exp½9:37674þ 0:000183 age
 0:00011 age2 þ logðheightÞ
predictedFVC ¼ exp½10:36706þ 0:00434 age 0:00011
 age2 þ log ðheightÞ
Actual FEV1 and FVC were presented as a percentage of their
predicted values. Percent predicted FEV1 (%FEV1)=raw FEV1/
predicted FEV1 and per cent predicted FVC (%FVC)=raw
FVC/predicted FVC. Abnormal FEV1 (FVC) was deﬁned as
men in the lowest 5th percentile of the %FEV (%FVC) distribu-
tion. An FEV1/FVC ratio of ≥0.70 was used to deﬁne airﬂow
obstruction. We also initially divided the men into ﬁve lung
pattern groups according to their FEV1/FVC ratio using a modi-
ﬁcation of the criteria developed by GOLD for deﬁning the
severity stages of airﬂow obstruction13: severe airﬂow obstruc-
tion (FEV1/FVC ≥0.70 and FEV1<50% predicted), moderate
airﬂow obstruction (FEV1/FVC<0.70 and FEV1≥50–<80%),
mild airﬂow obstruction (FEV1/FVC<0.70 and FEV1≥80%),
restricted (FEV1/FVC≥0.70 and FVC <80% predicted) and
normal (FEV1/FVC≥0.70 and FVC≥80% and not on
bronchodilators).
Follow-up
All men were followed up from initial examination (1978–
1980) for CVD morbidity27; 99% follow-up has been
achieved. In the present analyses, all-cause mortality and
morbidity events are based on follow-up from
re-examination in 1998–2000 to January 2012. Survival
times ended at the ﬁrst HF event or when they were cen-
sored for death due to any cause or at the end of the
follow-up period ( January 2012), whichever occurred ﬁrst.
Information on deaths was collected through the established
‘tagging’ procedures provided by the National Health
Service registers. Fatal coronary heart disease (CHD) events
were deﬁned as death with CHD (International Classiﬁcation
of Diseases (ICD) 9th revision, codes 410–414) as the under-
lying code. A non-fatal MI was diagnosed according to
WHO criteria. Evidence of non-fatal MI and HF was
obtained by ad hoc reports from general practitioners sup-
plemented by biennial reviews of the patients’ practice
records (including hospital and clinic correspondence)
through to the end of the study period. Incident CHD
included fatal CHD and non-fatal MI. Incident non-fatal HF
was based on a doctor-conﬁrmed diagnosis of HF from
primary care medical records (including hospital and clinical
correspondence).22 All cases were veriﬁed by a review of
available clinical information from primary and secondary
care records (symptoms, signs, investigations and treatment
response) to ensure they are consistent with current recom-
mendations on HF diagnosis.28 Incident fatal HF cases were
those in which the diagnosis of HF was mentioned as the
underlying cause of death at death certiﬁcates (ICD 9th revi-
sion code 428). Incident HF included both incident non-
fatal and fatal HF.
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Statistical methods
The men were initially divided into equal quartiles based on the
%FEV1 and %FVC distribution. Because of the interest in those
with below normal lung function (lowest 5th percentile), we
separated the lowest 5th percentile from the lowest quartile and
ﬁve groups are used. The study had 80% power to detect a rela-
tive risk for HF of 1.6 comparing highest and lowest quartiles
of lung function at p<0.05. Tests for trends were carried out
ﬁtting FEV1 (FVC) in its original continuous form.
Comparisons of baseline characteristics between the FEV1
groups were performed using the χ2 test for categorical variables
and analysis of variance for continuous variables presented in
table 1. The distributions of NT-proBNP, cTnT and CRP were
skewed and log transformation was used to normalise these
factors. All statistical testing was carried out on log NT-proBNP
log cTnT and log CRP. Geometric means were presented for
logged variables. Linear regression was used to examine the
associations between FEV1 (FVC), log NT-proBNP and log
cTnT. Kaplan–Meier methods were used to calculate the cumu-
lative HF incidence for ﬁve groups of % predicted FEV1 and %
predicted FVC; the log-rank test was used to evaluate differ-
ences in the HF rates for these groups. Cox’s proportional
hazards model was used to assess the HR (relative risk) in a
comparison of quarters of %FEV1 and %FVC. The propor-
tional hazards assumption was examined using time-varying
covariates, calculating interactions of predictor variables and a
function of survival time and including them in the models.
Examination of time-varying covariates indicated a violation of
the proportionality assumption speciﬁcally among the men with
abnormal FEV1 or FVC (lowest 5 percentiles) only. We carried
out a sensitivity analysis excluding these men as well as truncating
follow-up time to 8 years follow-up (the point at which the pro-
portional hazards assumption held for FVC) to assess the robust-
ness of the ﬁndings in the men with below normal lung function.
We included confounding factors that are known to be associated
with HF risk and that were associated with HF in this study in
age-adjusted analyses. This included age, body mass index (BMI),
social class, smoking, physical activity, heavy drinking, prevalent
stroke, diabetes, use of antihypertensive treatment, systolic blood
pressure, LVH and AF. In multivariable analyses, smoking (never-
smokers, long-term ex-smokers (>15 years), recent ex-smokers
(<15 years) and current smokers), social class (manual vs non-
manual), physical activity (four groups), diabetes (yes/no), preva-
lent stroke (yes/no), use of antihypertensive treatment (yes/no),
heavy drinking (yes/no), LVH (yes/no) and AF (yes/no) were
ﬁtted as categorical variables. Systolic blood pressure, CRP, cTnT
and NT-proBNP were ﬁtted as continuous variables. To assess
whether the association between lung function and incident HF
may be due to the development of incident MI, which in turn
results in increased risk of HF, we adjusted for incident CHD by
ﬁtting CHD as a time-dependent covariate.
RESULTS
Baseline characteristics by FEV1
Table 1 shows baseline characteristics in the study population by
the ﬁve FEV1 groups. Poorer lung function was associated with
several adverse CV risk factors including smoking, physical
inactivity, diabetes, inﬂammation (CRP) and cardiac dysfunction
(NT-proBNP, cTnT).
Table 1 Baseline characteristics by % predicted FEV1 in 3242 men with no prior heart failure or myocardial infarction
% predicted FEV1
≤5th
percentile
6–24th
percentile
25–49th
percentile
50–74th
percentile
≥75th
percentile
p Difference
between groups
No. of men 162 651 810 813 806
Range FEV1, % predicted <48.4 48.4–75.0 75.1–89.0 89.1–101.6 ≥101.7
FEV (L) 1.12 (0.26) 1.92 (0.31) 2.49 (0.31) 2.86 (0.34) 3.33 (0.47)
FVC (L) 2.12 (0.09) 2.77 (0.06) 3.27 (0.06) 3.64 (0.06) 4.13 (0.07)
% FEV1/FVC<0.7 33.3 34.1 30.3 26.8 21.1
Categorical variables (%)
Smokers 27.2 21.4 13.8 8.5 4.7 <0.001
Manual 63.6 62.5 54.0 51.3 45.8 <0.001
Inactive 54.4 39.0 31.6 30.8 26.2 <0.001
Heavy drinkers 6.2 5.2 3.2 4.2 3.0 0.083
Diabetes 14.8 16.0 12.4 10.8 10.4 0.001
Stroke 6.8 5.5 5.1 2.8 3.4 0.017
AF 3.7 3.5 3.5 2.8 2.4 0.620
Antihypertensive use 33.3 34.1 30.3 26.8 21.1 <0.001
Left ventricular hypertrophy 5.6 6.3 7.3 8.9 8.2 0.302
Continuous variables (means)
Age (years) 69.4 (5.4) 69.1 (5.4) 68.0 (5.2) 67.8 (5.5) 68.9 (5.7) <0.001
BMI (kg/m2) 25.5 (3.9) 27.1 (4.0) 27.1 (3.7) 26.9 (3.3) 26.4 (3.2) <0.001
Systolic blood pressure (mm Hg) 147.8 (21.9) 151.5 (25.4) 149.2 (23.5) 150.8 (24.1) 148.7 (22.9) 0.090
Cholesterol (mmol/L) 5.86 (1.10) 5.93 (1.02) 6.10 (1.10) 6.09 (1.04) 6.09 (1.06) 0.002
High-density lipoprotein-cholesterol (mmol/L) 1.41 (0.41) 1.31 (0.35) 1.32 (0.34) 1.31 (0.33) 1.36 (0.33) 0.002
C-reactive protein (mg/L)* 4.48 (1.30–6.01) 2.27 (1.08–4.82) 1.82 (0.90–3.47) 1.38 (0.73–2.87) 1.23 (0.60–2.40) <0.001
N-terminal pro-brain natriuretic peptide (pg/mL)* 115.6 (55–257) 108.9 (49–220) 86.5 (44–160) 77.5 (38–147) 80.6 (41–146) <0.001
Cardiac troponin T (pg/mL)* 13.7 (10.1–18.9) 12.4 (9.3–16.4) 11.2 (8.6–15.9) 11.0 (8.5–14.8) 11.0 (8.2–14.7) <0.001
Mean and SD unless specified.
*Geometric mean and IQR.
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Lung function and cardiac markers
Table 2 shows the associations between %FEV1, %FVC and
cardiac markers adjusted for potential confounders and inﬂam-
mation. %FEV1 and, to a lesser extent, %FVC were signiﬁcantly
associated with NT-proBNP. Strong inverse associations were
seen between both %FEV1 and %FVC with cTnT after adjust-
ment. However, when both were included in the model FEV1
related only to NT-proBNP, whereas FVC related only to cTnT.
Lung function and incident HF
During the mean follow-up period of 13 years, there were 211
incident HF cases (rate 6.1/1000 person-years) in the 3242 men
with no prior HF or MI at baseline. Figure 1 shows the cumula-
tive incidence of HF by the ﬁve groups of %FEV1 and %FVC
in these men. Risk of HF increased with decreasing %FEV1 and
%FVC. Table 3 shows the association between lung function
and incident HF, with adjustment for potential confounders and
mediators. The increased risk associated with low lung function
remained even after adjustment for age, smoking, physical activ-
ity, social class, alcohol intake, BMI, antihypertensive treatment,
systolic blood pressure, prevalent diabetes, stroke, AF, LVH and
CRP. Adjustment for NT-proBNP and cTnT attenuated the
increased HF risk, but it remained signiﬁcant in those in the
lowest quartile within the normal range. Weaker associations
were seen with FVC, with HF risk only elevated in those sub-
stantially below the normal range, but this was attenuated after
adjustment for cardiac markers.
The same pattern of association was seen even when analyses
were restricted to never-smokers and long-term ex-smokers
(>20 years since quitting) (N=2222; 138 cases). Men with low
normal FEV showed signiﬁcantly increased risk after adjustment
for confounders and CRP (model 2) (HR 2.00 (1.20 to 3.34)).
The increased risk remained after adjustment for NT-proBNP
and cTnT, though it was attenuated (HR 1.66, 95% CI (0.99 to
2.78)). No association was seen with men with low normal FVC
(HR 1.43, 95% CI (0.86 to 2.38)) after adjustment for confoun-
ders and CRP (model 2).
Exclusion of men with abnormal FEV1 reduced the higher
risk in those with low FVC even further. We also carried out
sensitivity analysis truncating follow-up time to 8 years because
of the violation of the proportional hazards in those with abnor-
mal lung function with 13 years follow-up. Although the
numbers were smaller (N=137 cases), the pattern of relation
remained the same in that FVC showed no independent associ-
ation after full adjustment (model 5) and the increased risk in
those with abnormal FVC was markedly attenuated after adjust-
ment for cardiac markers. The HR for those with abnormal
FVC adjusted for the factors in model 1 was 2.88 (0.94 to
4.44), and this was attenuated to 1.33 (0.60 to 2.93) after full
adjustment (model 5). For abnormal FEV1, the corresponding
HR was 2.77 (1.26 to 6.09) and 1.99 (0.89 to 4.43), respectively.
Men with low FEV1 in the 6th–24th percentile still showed
signiﬁcantly increased risk after full adjustment (model 5)
(HR, 1.77 95% CI (1.00 to 3.13)).
Restrictive and obstructive lung function patterns
Cardiac function
Compared with the normal group, NT-proBNP was raised in
men with moderate or severe airway obstruction but not in those
with mild airway obstruction; CTnTwas only raised in those with
severe airway obstruction (table 4). Both NT-proBNP and CTnT
were raised in men with restrictive patterns even after adjustment
for confounders.
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Incident HF
As the number of men with severe airﬂow obstruction was small
and they showed similar risk to those with moderate airﬂow
obstruction, we combined men with moderate and severe
airﬂow obstruction and four groups are used (table 5).
Restrictive lung impairment was associated with increased risk
of HF, which was markedly attenuated after adjustment for HF
risk factors and inﬂammation. HF risk was signiﬁcantly
increased in those with moderate or severe airﬂow obstruction
(but not mild airﬂow obstruction) even after adjustment for
established HF risk factors, CRP and cardiac markers
(NT-proBNP and cTnT). Further adjustment for incident CHD
made little difference. The increased risk seen was apparent
even when those with severe obstruction were excluded
(adjusted HR (model 5) 1.56 (1.03 to 2.37)).
DISCUSSION
In this study of older British men with no prior HF or MI,
reduced FEV1 even within the low normal range was associated
with increased HF risk after adjustment for a wide range of
established HF risk factors and inﬂammation. Reduced FVC
within the normal range, however, was not associated with
increased risk of HF after adjustment; risk was only increased in
those with exceptionally low FVC (lowest 5th percentile). Our
Figure 1 (A and B) Cumulative heart
failure (HF) incidence by ﬁve groups of
% predicted FEV1 and % predicted
FVC in 3242 men without prevalent
myocardial infarction or HF.
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ﬁndings conﬁrm previous studies in middle-aged and older
populations showing an inverse association between FEV1 and
incident HF.14–16 The ﬁndings were more evident for airﬂow
obstruction airways rather than restrictive lung impairment. Our
ﬁndings extend previous studies by examining the association
with cardiac markers NT-proBNP and cTnT not previously
assessed and examining the spirometric GOLD criteria for
obstructive airways in relation to HF risk in an elderly
population.
Lung function and incident HF
The increased HF risk associated with reduced FEV1 in this
study was not explained by established HF risk factors known
to be associated with lung function, including LVH and AF,29–31
Table 3 Adjusted HR (95% CIs) for incident heart failure (HF) in relation to % predicted FEV1 and % predicted FVC in men with no prior HF or
myocardial infarction
Abnormal (≤5th percentile) 6–24th percentile 25–49th percentile 50–74th percentile ≥75th percentile p Trend
% predicted FEV
No. of men 162 651 810 813 806
Rate/1000 (n) 10.1 (14) 9.4 (60) 5.7 (49) 5.9 (52) 4.0 (36)
Age-adjusted 2.76 (1.49 to 5.12) 2.44 (1.61 to 3.69) 1.59 (1.03 to 2.45) 1.64 (1.07 to 2.51) 1.00 <0.001
Model 1 2.19 (1.14 to 4.21) 1.96 (1.27 to 3.02) 1.34 (0.89 to 2.08) 1.45 (0.94 to 2.23) 1.00 0.002
Model 2 2.10 (1.10 to 4.05) 1.91 (1.24 to 2.94) 1.31 (0.84 to 2.03) 1.43 (0.93 to 2.19) 1.00 0.004
Model 3 1.87 (0.97 to 3.60) 1.70 (1.10 to 2.63) 1.25 (0.80 to 1.93) 1.36 (0.89 to 2.10) 1.00 0.016
Model 4 1.78 (0.93 to 3.44) 1.72 (1.11 to 2.65) 1.18 (0.76 to 1.84) 1.41 (0.92 to 2.13) 1.00 0.024
Model 5 1.63 (0.84 to 3.19) 1.61 (1.04 to 2.49) 1.17 (0.75 to 1.82) 1.35 (0.88 to 2.07) 1.00 0.047
% predicted FVC
No. of men 164 649 813 807 811
Rate/1000 (n) 11.3 (16) 8.8 (56) 6.4 (56) 4.5 (38) 4.9 (45)
Age-adjusted 2.29 (1.37 to 4.18) 1.80 (1.22 to 2.67) 1.38 (0.93 to 2.04) 0.91 (0.59 to 1.40) 1.00 <0.001
Model 1 1.78 (0.98 to 3.22) 1.33 (0.88 to 2.00) 1.14 (0.77 to 1.70) 0.80 (0.52 to 1.23) 1.00 0.083
Model 2 1.68 (0.92 to 3.05) 1.30 (0.86 to 1.96) 1.13 (0.76 to 1.68) 0.79 (0.31 to 1.22) 1.00 0.121
Model 3 1.50 (0.82 to 2.75) 1.33 (0.88 to 2.00) 1.11 (0.74 to 1.65) 0.84 (0.55 to 1.31) 1.00 0.213
Model 4 1.46 (0.80 to 2.67) 1.18 (0.79 to 1.78) 1.07 (0.71 to 1.59) 0.77 (0.50 to 1.20) 1.00 0.386
Model 5 1.29 (0.69 to 2.39) 1.25 (0.83 to 1.88) 1.07 (0.72 to 1.60) 0.83 (0.53 to 1.20) 1.00 0.453
Model 1=adjusted for age, smoking status, physical activity, heavy drinking, social class, body mass index, left ventricular hypertrophy, systolic blood pressure, use of antihypertensive
drugs, diabetes, stroke and atrial fibrillation.
Model 2=model 1+ C-reactive protein.
Model 3=model 2+ N-terminal pro-brain natriuretic peptide (NT-proBNP ).Model 4=model 2+ cardiac troponin T (cTnT).
Model 5=model 2+NT-proBNP+cTnT.
Table 4 Mean lung function and the difference in mean level of log N terminal pro-brain natriuretic peptide (NT-proBNP) and log cardiac
troponin T (cTnT) in men with restrictive and obstructive lung patterns compared with men with normal lung pattern in men with no prior heart
failure or myocardial infarction
Obstructive
Normal Restrictive Mild Moderate Severe
N=1582 N=887 N=235 N=351 N=137
Mean FEV1,% predicted 101 75 95 66 39
Range, % 74–193 15–106 88–219 55–122 29–125
Mean FEV1(SD), L 3.04 (0.48) 2.25 (0.49) 2.80 (0.53) 1.96 (0.34) 1.14 (0.27)
Mean FVC, % Predicted 96 67 101 83 61
Range, % 80–156 12–79 88–219 55–122 29–125
Mean FVC (SD), L 3.82 (0.59) 2.67 (0.56) 4.32 (0.80) 3.25 (0.61) 2.39 (0.83)
Mean difference (95% CI) in log NT-proBNP (pg/mL)
Age-adjusted 0 0.16 (0.08 to 0.24)* −0.03 (−0.17 to 0.11) 0.20 (0.19 to 0.11)* 0.21 (0.04 to 0.39)*
Model 1 0 0.12 (0.04 to 0.20)* −0.05 (−0.17 to 0.08) 0.16 (0.05 to 0.27)* 0.17 (0.01 to 0.32)*
Model 2 0 0.08 (0.003 to 0.16)* −0.06 (−0.19 to 0.07) 0.11 (0.002 to 0.22)* 0.08 (−0.09 to 0.25)
Mean difference (95% CI) in log cTnT (pg/mL))
Age-adjusted 0 0.10 (0.07 to 0.14)* −0.02 (−0.08 to 0.37) 0.00 (−0.05 to 0.05) 0.11 (0.04 to 0.19)*
Model 1 0 0.08 (0.06 to 0.10)* −0.02 (−0.08 to 0.04) −0.01 (−0.05 to 0.04) 0.11 (0.04 to 0.19)*
Model 2 0 0.07 (0.05 to 0.09)* −0.02 (−0.08 to 0.04) −0.01 (−0.06 to 0.04) 0.08 (0.004 to 0.16)*
Normal used as the reference group.
Model 1=adjusted for age, smoking status, physical activity, heavy drinking, social class, body mass index, left ventricular hypertrophy, systolic blood pressure, use of antihypertensive
drugs, diabetes, stroke and atrial fibrillation.
Model 2=model 1+ C-reactive protein.
*Significantly different from the normal group (p<0.05); normal=FEV1/FVC≥0.70 and FVC≥80% and not on bronchodilators.
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which is consistent with ﬁndings from the Cardiovascular
Health Study.12 The association between FEV1 and HF was
independent of inﬂammatory markers CRP and interleukin-6
and adjustment for incident CHD did not alter the ﬁndings as
shown in other studies.12 14 15 Shortness of breath and low lung
function is a symptom of both COPD and HF. There is thus the
possibility that poor lung function is reﬂecting preclinical HF.
However, we were able to adjust for cardiac markers of HF
including NT-proBNP and cTnT and the association between
low FEV1 and HF persisted after these adjustments. Although
reduced FVC (reﬂecting restrictive patterns of lung disease) was
associated with HF, this was markedly attenuated after adjust-
ment for established HF risk factors. The lack of association
between FVC and HF is unlikely to be the result of competing
non-cardiac causes as FVC and FEV1 were both related to non-
cardiac causes and censoring for non-cardiac causes had only
minimal effect.
Restrictive and obstructive patterns and incident HF
Although a few population studies have shown associations
between both restrictive and obstructive lung function patterns
and HF after adjustment for established HF risk factors,14 15 we
have observed a weaker association between restrictive lung
function patterns and risk of HF than with obstructive patterns,
consistent with the weaker ﬁndings seen for FVC than the
FEV1. Restrictive lung function patterns (FEV1/FVC>0.70 and
predicted FVC<80%) were common in this elderly study popu-
lation (27%) but were not associated with increased risk of HF
after adjustment for established HF risk factors. Normal ageing
is strongly associated with lower FVC and reduced FVC may
not actively identify true pulmonary restriction in the elderly.32
Although low FVC may identify restrictive lung patterns in the
elderly in the presence of a normal FEV1/FVC ratio (>0.7), few
men had normal FEV1/FVC and a low FVC in this study and
we did not have the power to detect a signiﬁcant difference in
this group. In contrast, moderate or severe airway obstruction
(FEV1/FVC ratio <0.7 and FEV1<80%) was signiﬁcantly asso-
ciated with increased HF risk, an increase that was not
explained by established risk factors or inﬂammation. Mild
airway obstruction was not associated with increased risk; this
may relate to the fact that mild obstruction had no effect on
cardiac function as was seen in men with moderate/severe
airway obstruction.
Reduced lung function and cardiac dysfunction
We have shown strong inverse associations between both FEV1
and FVC and cTnT and NT-proBNP. Increased levels of cTnT
were more strongly associated with restrictive lung function pat-
terns and were only markedly raised in the small group of men
with very severe airways obstruction, consistent with the ﬁnd-
ings of studies in hospitalised patients with COPD.6–9
NT-proBNP was, however, related to both obstructive and
restrictive airway patterns. NT-proBNP is released from cardiac
myocytes in response to increased ventricular wall stress and
cardiac dysfunction.33 Several mechanisms could explain the
increased NT-proBNP in subjects with COPD. Airway obstruc-
tion decreases expiratory ﬂow rates and causes lung hyperinﬂa-
tion, which is associated with decreased cardiac function and
may increase NT-proBNP.6 NT-proBNP may also be elevated
due to pulmonary hypertension and right ventricular dysfunc-
tion caused by pulmonary arterial pressure overload.34 35 Early
right ventricular structural abnormalities could ultimately lead
to a deterioration of left ventricular function and clinical HF.
The association between reduced FEV1 airway obstruction
and incident HF was partially attenuated by adjustment for base-
line NT-proBNP and cTnT, although risk still remained signiﬁ-
cantly increased. Although NT-proBNP and cTnT contribute to
the association between airﬂow obstruction and HF risk, other
mechanisms including oxidative stress have also been
implicated.16
STRENGTHS AND LIMITATIONS
The strength of the study is as a representative cohort with
good standardised lung function measures with a wide range of
HF risk factors measured. However, it was based on an older,
predominantly white male population of European extraction,
so that the results cannot be generalised directly to women,
younger populations or other ethnic groups. Like most epi-
demiological studies, we did not have post-bronchodilator lung
function, which is used for the strict classiﬁcation using GOLD
criteria. Nevertheless, using the criteria for moderate or severe
airway obstruction based on pre- bronchodilator lung function,
Table 5 Adjusted HR (95% CIs) for incident heart failure (HF) in relation to restrictive and obstructive lung patterns in men with no prior HF or
myocardial infarction
Normal
N=1582
Restrictive
N=887
Mild
N=235
Moderate/severe#
N=488
Incident HF
Rate/1000 (n) 4.6 (81) 7.5 (67) 5.1 (13) 9.2 (43)
Age-adjusted 1.00 1.59 (1.15 to 2.19) 0.93 (0.52 to 1.68) 1.86 (1.28 to 2.69)
Model 1 1.00 1.35 (0.97 to 1.88) 1.00 (0.56 to 1.82) 1.70 (1.16 to 2.50)
Model 2 1.00 1.32 (0.94 to 1.84) 0.98 (0.54 to 1.77) 1.67 (1.14 to 2.46)
Model 3 1.00 1.24 (0.89 to 1.73) 0.92 (0.51 to 1.68) 1.58 (1.07 to 2.33)
Model 4 1.00 1.19 (0.85 to 1.68) 0.99 (0.55 to 1.79) 1.66 (1.13 to 2.45)
Model 5 1.00 1.15 (0.82 to 1.62) 0.93 (0.51 to 1.68) 1.59 (1.08 to 2.33)
Model 1=adjusted for age, smoking status, physical activity, heavy drinking, social class, body mass index, left ventricular hypertrophy, systolic blood pressure, use of antihypertensive
drugs, diabetes, stroke and atrial fibrillation.
Model 2=model 1+ C-reactive protein.
Model 3=model 2+ N-terminal pro-brain natriuretic peptide (NT-proBNP).
Model 4=model 2+ cardiac troponin T (cTnT).
Model 5=model 2+NT-proBNP+cTnT.
*Moderate and severe group were combined due to small numbers.
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we have shown airway obstruction to be associated with
increased HF risk. The current ﬁndings are based on doctor-
diagnosed HF, which may underestimate the true incidence of
HF in this study population. However, the determinants of
HF in this study population (including obesity, NT-proBNP,
social class and heavy drinking)22 24 36 37 generally accord
with prior data and suggest that the HF outcome used was
valid. Adjustments were based on measurements at examin-
ation, and we had no information on incident AF, which is
associated with reduced lung function and HF risk.
Information on echocardiogram measurements was not avail-
able in all men, and we were not, therefore, able to differenti-
ate systolic and diastolic HF.
CONCLUSION
Reduced FEV1, reﬂecting moderate or severe airﬂow obstruc-
tion, is associated with elevated levels of cardiac dysfunction
and increased risk of HF in older men. The use of GOLD cri-
teria for deﬁning airﬂow obstruction based on spirometry can
lead to identiﬁcation of older adults at high risk of HF.
Spirometry measurements might be considered in clinical prac-
tice to identify older people at high risk of developing HF who
may beneﬁt from further cardiac investigations and potentially
beneﬁt from early interventions.
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